Comparative Pharmacology
Head-to-head clinical analysis: GLIADEL versus THIOTEPA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLIADEL versus THIOTEPA.
GLIADEL vs THIOTEPA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GLIADEL (carmustine implant) is a biodegradable wafer that delivers carmustine, a nitrosourea alkylating agent, directly into the tumor resection cavity. Carmustine alkylates DNA and RNA, leading to cross-linking and inhibition of DNA replication, ultimately causing cell death. It is cell cycle phase nonspecific.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription.
Gliadel (carmustine) implant is administered intraoperatively as 8 wafers, each containing 7.7 mg carmustine, placed in the resection cavity after tumor debulking. Maximum dose is 61.6 mg (8 wafers).
0.3-0.4 mg/kg intravenously every 1-4 weeks; or 0.5-1 mg/kg intravenously every 2-4 weeks (commonly 60 mg/m² IV every 1-4 weeks).
None Documented
None Documented
Clinical Note
moderateThiotepa + Digoxin
"Thiotepa may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateThiotepa + Digitoxin
"Thiotepa may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateThiotepa + Deslanoside
"Thiotepa may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateThiotepa + Acetyldigitoxin
"Thiotepa may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 1.3 hours for the active dianhydrogalactitol metabolite. Clinical context: short half-life supports local interstitial delivery with minimal systemic accumulation.
Terminal elimination half-life is approximately 1.5-4.5 hours. Clinically, due to rapid clearance, dosing intervals are typically every 1-4 weeks.
Primarily renal (60-70% as unchanged drug and metabolites) and biliary/fecal (15-20%). Approximately 10-15% is eliminated via exhaled air as CO2.
Primarily renal; 60-70% excreted unchanged in urine within 24-72 hours. Minor biliary/fecal elimination accounts for <10%.
Category C
Category D/X
Alkylating Agent
Alkylating Agent